About this research group
This research group aims to unravel the molecular processes underlying kidney regeneration and to identify new treatment targets to attenuate kidney disease progression.
read moreAbout this research group
This research group aims to unravel the molecular processes underlying kidney regeneration and to identify new treatment targets to attenuate kidney disease progression.
Research focuses on progressive kidney diseases leading to scarring of the glomerulus (glomerulosclerosis) and loss of the nephrons of the kidney. Current projects are aimed at unraveling the cellular and molecular processes underlying glomerulosclerosis, with an emphasis on cross-talk between the glomerular cells. In addition, research is aimed at unraveling the molecular pathways fundamental for survival of nephrons focusing on the intrinsic pathways essential for survival and regeneration of kidney epithelial and endothelial cells, respectively. The studies include the use of epithelial and endothelial cell lines, 3D kidney organoid culture and conditional knockout mouse models.
Aims
Our group has several aims.-
In previous studies in experimental models of glomerulosclerosis, we have shown that activated parietal epithelial cells (PECs) are crucially involved in the development of glomerulosclerosis.
read more
New treatment options for glomerulosclerosis
Currently, there are limited options for treatment of glomerulosclerosis available. In previous studies in experimental models of glomerulosclerosis, we have shown that activated parietal epithelial cells (PECs) are crucially involved in the development of glomerulosclerosis. These results were validated in human biopsies. From these studies we proposed that persistent activation of PECs is driving disease progression and that pharmacological inactivation of PECs represents an effective and targeted treatment option to slow loss of renal function. -
We aim to identify the yet unknown molecular processes underlying this phenotypic switch, which is a prerequisite for developing specific therapies for prevention and recovery of AKI/CKD.
read more